GO:0150102 negative regulation of monocyte activation: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0150102 (negative regulation of monocyte activation) describes any process that stops, prevents, or reduces the frequency, rate, or extent of monocyte activation, a critical checkpoint in innate immunity and inflammation.
• Key negative regulators include PPARα, MCPIP1, COMMD10, STAT3, and the ERK/CREB/miR-212-3p feedback loop, which restrain monocyte-driven inflammation through distinct molecular circuits.
• Dysregulation of this process contributes to sepsis-associated liver injury, inflammatory bowel disease, acute pulmonary oedema, and metabolic inflammation.
• Single-cell multi-omics (scRNA-seq and scATAC-seq) has begun to map the transcriptional and epigenetic blueprint of monocyte-to-macrophage and osteoclastogenic trajectories, revealing new negative regulatory nodes.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate negative regulators in monocyte activation pathways.
• Targeting negative regulators of monocyte activation is a promising therapeutic strategy for inflammatory and metabolic diseases, but requires precise cell-type-specific validation.
Description
Monocytes are circulating innate immune cells that, upon activation, differentiate into macrophages or dendritic cells and drive inflammation, tissue repair, and host defense. Unchecked monocyte activation contributes to chronic inflammatory diseases, sepsis, and metabolic disorders. The Gene Ontology term GO:0150102, negative regulation of monocyte activation, captures the biological processes that restrain this activation, thereby maintaining immune homeostasis. Understanding these regulatory mechanisms is essential for developing therapies that selectively dampen pathological inflammation without compromising immunity. Recent studies have identified several negative regulators, including PPARα, which interacts with the cGAS-STING pathway to limit monocyte activation in diabetes, and MCPIP1, which restrains intestinal monocyte-to-macrophage maturation via an ATF3-AP1S2 axis. Other work has shown that COMMD10 deficiency impairs the regulation of Ly6C(hi) monocyte-driven inflammation and disrupts gut barrier function, while STAT3 negatively regulates STAT1-dependent inflammatory gene activation in type I interferon responses. These findings underscore the diversity of molecular circuits that enforce negative regulation of monocyte activation. This article synthesizes the current knowledge on GO:0150102, covering its definition, key genes, regulatory mechanisms, disease relevance, and experimental models for research.
negative regulation of monocyte activation At A Glance
| GO ID | GO:0150102 |
|---|---|
| GO term | negative regulation of monocyte activation |
| Ontology | biological_process |
| Synonym | repression of monocyte activation |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of monocyte activation. |
| Major function | Restraining monocyte activation to prevent excessive inflammation and maintain immune homeostasis. |
| Key regulators | PPARα, MCPIP1, COMMD10, STAT3, ERK/CREB/miR-212-3p feedback loop |
| Associated diseases | Sepsis, inflammatory bowel disease, acute pulmonary oedema, diabetes-associated inflammation |
| Research methods | scRNA-seq, scATAC-seq, CRISPR screens, flow cytometry, cytokine profiling |
What Is GO:0150102?
According to the Gene Ontology, GO:0150102 (negative regulation of monocyte activation) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of monocyte activation. Monocyte activation encompasses the cellular changes that convert a resting monocyte into an activated state capable of cytokine production, phagocytosis, antigen presentation, and differentiation. Negative regulation therefore includes molecular brakes such as inhibitory signaling pathways, transcriptional repressors, microRNAs, and feedback loops that limit these responses.
Why Is negative regulation of monocyte activation Important in Cell Biology?
Negative regulation of monocyte activation is a fundamental safeguard against uncontrolled inflammation. Monocytes are among the first responders to infection and tissue damage, but their overactivation can lead to cytokine storms, tissue destruction, and chronic inflammatory diseases. Elucidating the molecular mechanisms that put the brakes on monocyte activation provides insights into disease pathogenesis and identifies potential therapeutic targets for conditions such as sepsis, inflammatory bowel disease, and metabolic disorders.
• Prevents excessive cytokine production and tissue damage during infection.
• Maintains gut barrier function by controlling Ly6C(hi) monocyte-driven inflammation.
• Limits monocyte-to-macrophage differentiation in sepsis-associated liver injury.
• Modulates osteoclastogenic trajectories, linking monocyte regulation to bone metabolism.
• Influences acute pulmonary oedema outcomes via systemic markers of monocyte activation.
• Provides a therapeutic rationale for targeting PPARα, MCPIP1, and COMMD10 in inflammatory diseases.
• Involves microRNA feedback loops (miR-212-3p) that can be exploited for RNA-based therapeutics.
• Highlights the role of STAT3 as a negative regulator of STAT1-dependent inflammatory gene activation.
• Offers biomarkers for disease severity and treatment response.
• Enables CRISPR-based functional genomics to identify novel negative regulators.
What Happens During negative regulation of monocyte activation?
Initiation of negative feedback loops
In simple terms: When monocytes start to activate, they also turn on brakes to prevent runaway inflammation.
Negative regulation of monocyte activation often begins with the induction of feedback inhibitors upon initial activation signals. For example, in HBeAg-induced macrophage activation, the ERK/CREB pathway drives expression of miR-212-3p, which then inhibits further activation, forming a negative feedback loop. Similarly, STAT3 is activated by type I interferons and subsequently suppresses STAT1-dependent inflammatory gene activation, providing a brake on monocyte/macrophage responses.
Transcriptional and epigenetic control
In simple terms: Special proteins and chemical tags on DNA can shut down genes that would otherwise keep monocytes active.
Transcriptional repressors and epigenetic modifiers enforce long-term negative regulation. MCPIP1 restrains mucosal inflammation by orchestrating intestinal monocyte-to-macrophage maturation through an ATF3-AP1S2 axis, involving transcriptional reprogramming. Integrative single-cell RNA-seq and ATAC-seq has revealed transcriptional and epigenetic blueprints guiding osteoclastogenic trajectories, highlighting how chromatin accessibility changes accompany monocyte differentiation and activation.
Metabolic and signaling checkpoints
In simple terms: Metabolic sensors and signaling pathways act as checkpoints that can stop monocytes from becoming overactive.
PPARα negatively regulates monocyte activation by interacting with the cGAS-STING pathway, thereby limiting inflammatory responses in diabetes. COMMD10 deficiency impairs the regulation of Ly6C(hi) monocyte-driven inflammation, leading to disrupted gut barrier function, indicating that COMMD10 is a critical checkpoint. These examples illustrate how metabolic and signaling nodes integrate to suppress monocyte activation.
Resolution of activation and return to homeostasis
In simple terms: After the threat passes, monocytes are returned to a resting state to avoid chronic inflammation.
Negative regulation also involves active resolution programs that restore monocytes to a resting state. ASGR1 promotes liver injury in sepsis by modulating monocyte-to-macrophage differentiation via the NF-κB/ATF5 pathway; interference with this pathway may enhance negative regulation. Systemic markers of monocyte activation in acute pulmonary oedema suggest that resolution involves downregulation of activation markers. The interplay between activating and inhibitory signals determines the balance between effective immunity and pathological inflammation.
Key Genes Involved in GO:0150102 negative regulation of monocyte activation
The following genes and proteins have been experimentally implicated in the negative regulation of monocyte activation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPARα | Negative regulator of monocyte activation via cGAS-STING interaction | Diabetes-associated inflammation |
| MCPIP1 | Restrains intestinal monocyte-to-macrophage maturation via ATF3-AP1S2 axis | Mucosal inflammation, IBD |
| COMMD10 | Regulates Ly6C(hi) monocyte-driven inflammation and gut barrier function | Gut barrier integrity, colitis |
| STAT3 | Negative regulation of STAT1-dependent inflammatory gene activation | Type I interferon responses |
| miR-212-3p | Mediates ERK/CREB negative feedback loop in macrophage activation | HBeAg-induced macrophage activation |
| ATF3 | Transcription factor involved in MCPIP1-mediated monocyte maturation control | Intestinal inflammation |
| AP1S2 | Component of the ATF3-AP1S2 axis in monocyte maturation | Mucosal inflammation |
| ATF5 | Modulates monocyte-to-macrophage differentiation via NF-κB pathway | Sepsis-associated liver injury |
| NF-κB | Central inflammatory transcription factor modulated by ASGR1/ATF5 | Sepsis, liver injury |
| cGAS-STING | Innate immune pathway interacting with PPARα | Metabolic inflammation |
| ERK | Kinase in the ERK/CREB/miR-212-3p feedback loop | Macrophage activation |
| CREB | Transcription factor driving miR-212-3p expression | Macrophage activation |
| ASGR1 | Promotes monocyte-to-macrophage differentiation in sepsis | Liver injury, sepsis |
| Ly6C | Marker of inflammatory monocytes regulated by COMMD10 | Gut inflammation |
| STAT1 | Target of STAT3-mediated negative regulation | Interferon responses |
| RUNX2 | Transcription factor in osteoclastogenic trajectory | Bone metabolism |
| NFATc1 | Master regulator of osteoclastogenesis | Osteoclast differentiation |
How Is negative regulation of monocyte activation Regulated?
Negative regulation of monocyte activation is itself tightly regulated at multiple levels. The ERK/CREB/miR-212-3p axis constitutes a negative feedback loop that is induced upon activation and subsequently dampens inflammatory gene expression. STAT3 acts as a negative regulator of STAT1-dependent inflammatory gene activation in type I interferon responses, illustrating cross-talk between signaling pathways. PPARα interacts with the cGAS-STING pathway to suppress monocyte activation, linking metabolic sensing to innate immune regulation. COMMD10 is required to restrain Ly6C(hi) monocyte-driven inflammation, and its deficiency leads to disrupted gut barrier function. MCPIP1 controls intestinal monocyte-to-macrophage maturation via an ATF3-AP1S2 axis, providing a transcriptional layer of regulation. These mechanisms collectively ensure that monocyte activation is transient and self-limiting.
negative regulation of monocyte activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARα | Diabetes-associated inflammation | Ppara knockout mice, monocyte-specific overexpression |
| MCPIP1 | Inflammatory bowel disease | Zc3h12a knockout mice, intestinal organoids |
| COMMD10 | Gut barrier dysfunction, colitis | Commd10 knockout mice, DSS-induced colitis |
| ASGR1 | Sepsis-associated liver injury | Asgr1 knockout mice, LPS-induced sepsis |
| STAT3 | Type I interferon responses | Stat3 conditional knockout macrophages |
Sepsis and liver injury
ASGR1 promotes liver injury in sepsis by modulating monocyte-to-macrophage differentiation via the NF-κB/ATF5 pathway, suggesting that negative regulation of monocyte activation is impaired in sepsis. Systemic markers of monocyte activation are elevated in acute pulmonary oedema, a condition often associated with systemic inflammation.
Inflammatory bowel disease
MCPIP1 restrains mucosal inflammation by orchestrating intestinal monocyte-to-macrophage maturation via an ATF3-AP1S2 axis, and its dysfunction may contribute to inflammatory bowel disease. COMMD10 deficiency impairs the regulation of Ly6C(hi) monocyte-driven inflammation and disrupts gut barrier function, linking defective negative regulation to colitis.
Metabolic inflammation and diabetes
PPARα negatively regulates monocyte activation through interaction with the cGAS-STING pathway, and dysregulation of this axis may exacerbate diabetes-associated inflammation. This highlights the intersection of metabolic and immune regulation in diabetes.
Bone metabolism and osteoclastogenesis
Integrative single-cell RNA-seq and ATAC-seq has identified transcriptional and epigenetic blueprints guiding osteoclastogenic trajectories, which are derived from monocyte/macrophage lineage cells. Negative regulation of monocyte activation may influence osteoclast differentiation and bone homeostasis.
From negative regulation of monocyte activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PPARα negatively regulate monocyte activation via cGAS-STING? | Ppara knockout and cGAS-STING reporter monocytes |
| What is the role of MCPIP1 in intestinal monocyte maturation? | Zc3h12a knockout mice and intestinal monocyte cultures |
| How does COMMD10 control Ly6C(hi) monocyte inflammation? | Commd10 knockout mice and adoptive transfer |
| Can miR-212-3p mimic suppress macrophage activation? | miR-212-3p overexpression in macrophages |
| What is the epigenetic blueprint of osteoclastogenic trajectory? | scRNA-seq and scATAC-seq of monocyte-derived osteoclasts |
| Does STAT3 negatively regulate STAT1-dependent inflammatory genes? | Stat3 knockout macrophages and interferon stimulation |
How to Study the negative regulation of monocyte activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| scRNA-seq | Transcriptional profiles at single-cell resolution | Monocyte heterogeneity and activation states |
| scATAC-seq | Chromatin accessibility | Epigenetic regulation of monocyte differentiation |
| Flow cytometry | Surface marker expression | Quantification of activated monocytes |
| Cytokine ELISA | Secreted inflammatory cytokines | Functional assessment of monocyte activation |
| Western blot | Protein expression and phosphorylation | Signaling pathway analysis |
| CRISPR knockout screening | Gene function at scale | Discovery of negative regulators |
| Luciferase reporter assay | Transcriptional activity | Promoter regulation by transcription factors |
| Immunoprecipitation | Protein-protein interactions | Complex formation (e.g., PPARα-cGAS) |
Single-cell transcriptomics and epigenomics
Single-cell RNA-seq combined with ATAC-seq enables mapping of transcriptional and epigenetic changes during monocyte activation and differentiation. This approach has been used to identify regulatory blueprints guiding osteoclastogenic trajectories, revealing potential negative regulatory nodes.
Flow cytometry and cytokine profiling
Flow cytometry can quantify surface activation markers on monocytes, while cytokine profiling (e.g., TNF-α, IL-6) measures functional activation. These methods are used to assess the impact of negative regulators such as PPARα and COMMD10.
CRISPR screens and functional genomics
Pooled CRISPR knockout screens in monocyte/macrophage cell lines or primary cells can identify novel negative regulators of activation. Candidate genes can then be validated individually using targeted knockout or overexpression.
Molecular biology and signaling assays
Western blotting, immunoprecipitation, and luciferase reporter assays are used to dissect signaling pathways such as ERK/CREB/miR-212-3p and STAT3-STAT1 interactions.
How CRISPR Can Be Used to Study GO:0150102 negative regulation of monocyte activation
Knockout
CRISPR knockout of candidate negative regulators (e.g., PPARα, MCPIP1, COMMD10) in monocyte cell lines or primary monocytes can reveal their necessity in restraining activation. For example, Commd10 knockout mice exhibit exacerbated Ly6C(hi) monocyte-driven inflammation.
Point Mutation
Point mutations can be introduced to disrupt specific domains or phosphorylation sites in negative regulators. For instance, mutating the STAT3 DNA-binding domain could abrogate its negative regulation of STAT1-dependent genes.
Knock-in
Knock-in of tagged versions (e.g., FLAG, HA) of negative regulators allows for chromatin immunoprecipitation and proteomic studies. This can help map the interactome of proteins like PPARα in monocytes.
Overexpression
Overexpression of negative regulators such as miR-212-3p or MCPIP1 can suppress monocyte activation and serve as a gain-of-function validation. This approach is useful for testing therapeutic potential.
How EDITGENE Supports negative regulation of monocyte activation Research
Researchers studying negative regulation of monocyte activation-related genes often need to determine whether a candidate gene is causally involved in restraining monocyte activation or is merely a bystander. CRISPR-based models provide the gold standard for establishing causality, and EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of monocyte activation research.
Frequently Asked Questions About negative regulation of monocyte activation
What is negative regulation of monocyte activation (GO:0150102)?
It is any biological process that stops, prevents, or reduces the frequency, rate, or extent of monocyte activation, as defined by the Gene Ontology.
What genes are involved in negative regulation of monocyte activation?
Key genes include PPARα, MCPIP1, COMMD10, STAT3, and the ERK/CREB/miR-212-3p feedback loop components.
How does PPARα negatively regulate monocyte activation?
PPARα interacts with the cGAS-STING pathway to suppress monocyte activation, thereby limiting inflammation in diabetes.
What is the role of MCPIP1 in monocyte activation?
MCPIP1 restrains mucosal inflammation by orchestrating intestinal monocyte-to-macrophage maturation via an ATF3-AP1S2 axis.
How does COMMD10 regulate monocyte-driven inflammation?
COMMD10 is required to restrain Ly6C(hi) monocyte-driven inflammation; its deficiency disrupts gut barrier function.
What diseases are associated with defective negative regulation of monocyte activation?
Sepsis-associated liver injury, inflammatory bowel disease, acute pulmonary oedema, and diabetes-associated inflammation.
What research methods are used to study negative regulation of monocyte activation?
Single-cell RNA-seq, ATAC-seq, flow cytometry, cytokine profiling, CRISPR screens, and signaling assays.
Can CRISPR be used to study negative regulators of monocyte activation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes.
What is the ERK/CREB/miR-212-3p feedback loop?
It is a negative feedback loop where ERK/CREB induces miR-212-3p, which then inhibits HBeAg-induced macrophage activation.
How does STAT3 negatively regulate monocyte activation?
STAT3 is activated by type I interferons and suppresses STAT1-dependent inflammatory gene activation.
Conclusion
Negative regulation of monocyte activation (GO:0150102) is a vital biological process that prevents excessive inflammation and maintains immune homeostasis. Key regulators such as PPARα, MCPIP1, COMMD10, and STAT3, along with the ERK/CREB/miR-212-3p feedback loop, have been experimentally validated in diverse contexts. Dysregulation of these mechanisms contributes to sepsis, inflammatory bowel disease, metabolic inflammation, and other disorders. Advances in single-cell multi-omics and CRISPR functional genomics are accelerating the discovery of new negative regulators and therapeutic targets. Continued research into GO:0150102 will deepen our understanding of monocyte biology and open new avenues for treating inflammatory diseases.
References
- 1. Dong L et al.. 2023. Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway.. Diabetes 72(7):958-972 PMID: 37058417
- 2. Shi R et al.. 2023. ASGR1 promotes liver injury in sepsis by modulating monocyte-to-macrophage differentiation via NF-κB/ATF5 pathway.. Life Sci 315:121339 PMID: 36621538
- 3. Lu H et al.. 2023. MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.. Gut 72(5):882-895 PMID: 37015751
- 4. Das A et al.. 2025. Integrative single-cell RNA-seq and ATAC-seq identifies transcriptional and epigenetic blueprint guiding osteoclastogenic trajectory.. J Bone Miner Res 40(10):1127-1143 PMID: 40577680
- 5. Chen W et al.. 2020. Negative feedback loop of ERK/CREB/miR-212-3p inhibits HBeAg-induced macrophage activation.. J Cell Mol Med 24(18):10935-10945 PMID: 32767729
- 6. Dixon DL et al.. 2021. Systemic Markers of Monocyte Activation in Acute Pulmonary Oedema.. Heart Lung Circ 30(3):404-413 PMID: 32713768
- 7. Ho HH et al.. 2006. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation.. J Biol Chem 281(20):14111-8 PMID: 16571725
- 8. Mouhadeb O et al.. 2018. Impaired COMMD10-Mediated Regulation of Ly6C(hi) Monocyte-Driven Inflammation Disrupts Gut Barrier Function.. Front Immunol 9:2623 PMID: 30487795
